Geron Discontinues Phase III Myelofibrosis Trial After Survival Goal Setback
Why the Geron IMpactMF trial discontinued: monitors judged the survival goal unlikely. Rytelo’s MDS approval is unaffected.
Why the Geron IMpactMF trial discontinued: monitors judged the survival goal unlikely. Rytelo’s MDS approval is unaffected.